New mRNA Vaccine facility

NFOE designed and executed the Moderna Montreal metropolitan project, a center of excellence for messenger RNA (mRNA) vaccines. The project includes a research and development center and a production facility with a capacity varying between 30 to 100 million doses annually, depending on need. This project strengthens Canada's position in global research and biofabrication capabilities. It also enables Quebec researchers to be at the forefront of the response to anticipated pandemics and the production of next-generation medications, particularly against cancers, heart diseases, and autoimmune diseases. As Moderna's first production site in Canada, it marks a significant advancement for the country, making it self-sufficient in mRNA vaccines.

Moderna, an icon in global biotechnology, is an American company founded in 2010 aiming to develop treatments based on mRNA technology. The company has created one of the mRNA vaccines against COVID-19, recognized by Health Canada and the FDA, serving international markets. The pharmaceutical company employs over 3,000 people, mainly in the United States. The new facility built by NFOE will support the creation of jobs in local research and biofabrication. The project is part of the Canadian Strategy for Biofabrication and Life Sciences, aimed at rebuilding the national industry.

NFOE designed a high-quality building envelope, predominantly composed of prefabricated insulated concrete panels, providing superior performance to conventional envelope systems assembled on-site. The continuity of insulation and waterproofing is more reliable in a prefabricated system. This type of construction improves envelope performance and minimizes risks to the occupants' health. The fenestration allows for beneficial natural light in the interior spaces, enhancing the well-being of the occupants.